PRAGUE-17
2020
Left Atrial Appendage Closure versus Novel Anticoagulation Agents in Atrial Fibrillation
In 402 high-risk patients with non-valvular atrial fibrillation, percutaneous left atrial appendage closure was non-inferior for a composite of cardiovascular and bleeding events compared with direct oral anticoagulants.
Result
Efficacy: Composite of stroke, TIA, systemic embolism, CV death, major/CRNM bleeding, or procedure/device complicationssubdistribution HR 0.84 (95% CI 0.53-1.31) · P = 0.004
Below 1 favours percutaneous left atrial appendage closure, above 1 favours direct oral anticoagulants.
- Absolute difference
- 2.43 points
The absolute difference is derived from the event rates.
Also reported: LAA closure non-inferior to DOACs.
- Subtopic
- LAAO
- Design
- Multicentre open-label non-inferiority RCT
- Relevance
- Supporting: context rather than must-know.
- Cited in
- ESC 2024 AFACC/AHA 2023 AF
- Source
- Osmancik P, et al. J Am Coll Cardiol. 2020;75(25):3122-3135.doi 10.1016/j.jacc.2020.04.067
Discussion & critique
Modest size and few events limit precision, and findings apply to high-bleeding-risk patients. First RCT to show LAA occlusion non-inferior to DOACs, extending device evidence beyond the warfarin era.